Pooled analyses show NILEMDO ® ▼ significantly lowers cholesterol in different subgroups in Phase 3 data presented at AHA 2020
Daiichi Sankyo Europe GmbH (hereafter, ‘Daiichi Sankyo’) today announced results from two pooled analyses from four Phase 3 clinical trials for bempedoic acid. The data were presented at the virtual American Heart Association (AHA) Scientific Sessions 2020.
One pooled analysis including 3,621 patients explored low-density lipoprotein cholesterol (LDL-C) reduction in male participants compared to female participants across two pools of patients; an on-statins pool and a statin-intolerant pool.**3 Results showed that bempedoic acid significantly lowered LDL-C at Week 12 in both sexes compared with placebo.3 In the on-statins pool bempedoic acid significantly reduced LDL-C by 21.2% in female participants vs. 17.4% in male participants (placebo-corrected; interaction p value = 0.044). In the statin-intolerant pool LDL-C was reduced by 27.7% in female participants vs. 22.1% in male participants (placebo-corrected; interaction p value = 0.079), which was not statistically significant.3 Baseline levels of LDL-C were slightly higher in female participants.3 Bempedoic acid was generally well tolerated by both sexes in both pools.3
In Europe, cardiovascular disease causes a greater proportion of deaths among women (51%) than men (42%) overall, killing twice as many women as all forms of cancer combined.4 Evidence shows that women have often been underrepresented in clinical trials of lipid-lowering therapies and cardiovascular outcomes, and analyses of trial data by sex are deficient in cardiovascular research.4,5
“These data demonstrate the benefits of bempedoic acid in both women and men who struggle to keep their LDL-C levels low, many of whom are already taking other lipid-lowering therapies to try and reach their recommended LDL-C levels,” said Anne C Goldberg, Professor of Medicine, Washington University School of Medicine, USA. “As women have been historically underrepresented in clinical trials, and we know that both sexes are affected differently by disease, these results presented today are important in analysing the sexes separately and understanding the impact of treatment on both groups.”
“It is important for the future of patient care that we examine bempedoic acid data across multiple subgroups to help identify different patients that may benefit from this treatment. These data further add to the robust evidence behind bempedoic acid as an option that can be added on to existing lipid-lowering therapies to further reduce LDL-C levels, helping patients take back control of their cholesterol,” said Wolfgang Zierhut MD, Head Antithrombotic and Cardiovascular Therapeutic Area at Daiichi Sankyo Europe. “With up to 80% of patients not reaching guideline-recommended LDL-C goals despite receiving treatments such as statins and other lipid-lowering therapies, we are committed to continuing to help provide solutions to support these patients.”
The second pooled analysis presented at AHA 2020 assessed the efficacy and safety of bempedoic acid in patients from four Phase 3 clinical trials who were unable to tolerate statins.6 Results showed that bempedoic acid significantly reduced LDL-C by an average of –26.5% (95% CI: –29.7, –23.2) vs. placebo in patients unable to use statins. Bempedoic acid was shown to be generally well-tolerated in patients with hypercholesterolaemia unable to tolerate a statin.6
*Note: Daiichi Sankyo Europe strives to be inclusive in our language. In this press release, we follow the recommendation for reporting of demographic data in research articles of the language guidance outlined in “Reporting Sex, Gender, or Both in Clinical Research?” from The Journal of the American Medicine Association (JAMA). November 8, 2016 Volume 316, Number 18
**Note: the on-statins pool were patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH) who were receiving background lipid-lowering therapy, including maximally tolerated statins. The statin-intolerant pool were patients with a history of problems taking statins and included patients who were taking no statins or no more than the lowest approved starting dose of a statin.
– ENDS –
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol, and which can be combined with other oral treatments to help lower cholesterol even further.1 NILEMDO® inhibits ATP citrate lyase (ACL), an enzyme which is involved in the production of cholesterol in the liver.1
NILEMDO® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet1
- in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
- alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
NILEMDO® acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to statin or other lipid-lowering therapies.1 Due to its unique mechanism of action, NILEMDO® is not activated in skeletal muscle which decreases the potential for muscle-related side effects.1,2
NUSTENDI® is a new oral treatment which combines two complementary ways of reducing cholesterol in a convenient once-daily tablet. NUSTENDI® is a fixed dose combination tablet containing bempedoic acid (the active pharmaceutical ingredient in NILEMDO®) and ezetimibe.7
NUSTENDI® has been approved for use in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:7
- in combination with a statin in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe,
- alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone,
- in patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without a statin.
Daiichi Sankyo Europe has licensed exclusive commercialisation rights to NILEMDO® and NUSTENDI® in the European Economic Area, Turkey and Switzerland from Esperion and is the full Marketing Authorisation Holder in these territories.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centred around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.
1 European Medicines Agency. NILEMDO® Summary of Product Characteristics. March 2020.
2 Pinkosky SL, et al. Liver- specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Communications. 2016; 7:13457. DOI:10.1038/ncomms13457.
3 Goldberg AC, et al. Efficacy and safety of bempedoic acid by sex: pooled analyses from phase 3 trials. Poster presentation at American Heart Association Scientific Sessions. November 2020, Abstract P742.
4 Tamargo J, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J CardiovascPharmacother. 2017; 3:163-182.
5 Cholesterol Treatment Trialists' (CTT) Collaboration, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385:1397-1405.
6 Laufs U, et al. Efficacy and safety of bempedoic acid in patients who cannot tolerate any dose of a statin: pooled analyses from phase 3 clinical trials. Poster presentation at American Heart Association Scientific Sessions. November 2020, Abstract P2139.
7 European Medicines Agency. NUSTENDI® Summary of Product Characteristics. March 2020.
Dr. Wolfgang Schiessl (Europe)
Daiichi Sankyo Europe GmbH
Director Product PR and Communications, Cardiovascular Europe
+49 151 1714 7317
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
C3.ai Digital Transformation Institute Announces Shell as New Industry Partner4.3.2021 20:00:00 CET | Press release
The C3.ai Digital Transformation Institute (DTI) today announced that global energy company Shell is the newest industry partner to join the consortium of universities, national laboratories, and companies that make up the Institute. Shell’s Chief Scientist - Computation and Data Science Detlef Hohl will represent the company in the consortium. The DTI Industry Partner Program enables leading companies from around the world to engage with DTI researchers and activities and to contribute data sets that will be available for research after anonymization. Industry partners also are encouraged to engage with Institute researchers and collaborate on research projects as well as participate in DTI conferences. DTI recently released its second call for proposals to fund advanced research projects focused on applying digital transformation and AI to address energy and climate security. “Shell has established clear leadership in new energy, having laid out its ‘Powering Progress’ commitment to
Dole Launches “The Dole Way” Sustainability Campaign4.3.2021 19:22:00 CET | Press release
Dole Food Company announced today the launching of an integrated sustainability campaign aimed at amplifying its commitment to the key enterprise-wide sustainability goals launched in 2020 under “The Dole Way.” As a leader in the produce industry for over 150 years, Dole believes in acting on its promise to increase sustainability, transparency, corporate responsibility and trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005912/en/ The Dole Way framework paves the way for further improvements in areas where Dole believes it can make the biggest positive impacts (Photo: Business Wire) “The Dole Way” campaign kicked-off with a live, internal event on February 25, led by Dole’s president and chief executive officer, Johan Linden, and will be sustained over the next several months through integrated earned and owned social media efforts. “The Dole Way” campaign illustrates a path of transformation that will recognize
Milliken & Company Appoints Cindy Boiter as Executive Vice President, Chemical Division President4.3.2021 18:00:00 CET | Press release
Milliken & Company is pleased to announce Cindy Boiter has been promoted to executive vice president and president of Milliken’s Chemical Division. Effective March 15, she will step into the role currently held by David Moody as he transitions to a role outside of Milliken. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005823/en/ Cindy Boiter, newly announced executive vice president and president of Milliken's Chemical Division (Photo: Business Wire) “It is an exciting appointment for our company, as Cindy will become the first-ever woman division president at Milliken,” shares Halsey Cook, president and CEO for Milliken. “She is uniquely qualified to lead our chemical division thanks to her extensive experience in the division, the acquisitions she has completed and her embodiment of Milliken’s purpose.” Boiter joined Milliken’s Chemical Division in 2012 as marketing, strategy and business development director and p
Verimatrix Takes Home Two 2021 Gold Cybersecurity Excellence Awards4.3.2021 17:45:00 CET | Press release
Regulatory News: Verimatrix, (Paris:VMX) (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it won two gold awards in this year’s Cybersecurity Excellence Awards program. Verimatrix Multi-DRM won in the Digital Rights Management (North America) category while Verimatrix’s Application Shielding suite of products were recognized in the Automotive Security IoT (North America) category. It marks the third straight year the company has received honors from the award program that pays tribute to a wide variety of cybersecurity companies spanning the world’s largest vendors to the most recent startups. Verimatrix’s code shielding and embedded security capabilities picked up kudos in previous years. “The automotive industry stands as a superb example of a vertical where Verimatrix uniquely addresses multiple cybersecurity needs – in this case, vital components such as keyless entry mobile apps and infotainment systems, said A
Andersen Global Strengthens Presence with Jordanian Tax Firm4.3.2021 15:30:00 CET | Press release
Andersen Global enters into a Collaboration Agreement with Amman-based tax firm Al-Tillawi & Al-Khateeb Co., adding dimension to the existing capabilities of the organization’s member firm in Jordan. Founded in 1996, Al-Tillawi & Al-Khateeb Co. provides a wide range of tax and advisory services including corporate and family business, employment, mergers and acquisitions, outsourcing and social security as well as IT solutions. The firm, led by Managing Partner Waleed Al Tillawi, serves a broad clientele in industries such as power and energy, technology and communication, hotel and tourism, finance and retail. “Our team’s dedication to transparency and independence have been the driving forces behind the high-quality client services we provide,” Waleed said. “Collaborating with like-minded individuals at Andersen Global will allow us to take our service offerings to the next level and expand our reach more broadly. We look forward to working with the organization’s member and collabor
Business Finland Awarded Funding for Medicortex4.3.2021 15:08:00 CET | Press release
Medicortex Finland Oy, a Finnish biotechnology company focusing on brain injury diagnostics and drug development, announces receiving funding from the Finnish government innovation funding branch Business Finland. The funds are meant to expedite the development of a medical diagnostic test to improve detection of traumatic brain injury (TBI) and concussion. Medicortex has discovered novel biomarkers of head injury in body fluids such as saliva and urine. The funding which covers 50% of the expenses will support a project consisting of the development of a test kit for easy and rapid detection of brain injury and concussion. The objective of the company’s biomarker program is to generate new means for early detection of brain injury, which is a global unresolved issue. Current methods of brain injury diagnostics which are based on neurological examination and imaging do not reliably detect mild injury, yet they can have implications that are fatal or develop into a chronic condition if
Kent County Council Switches to Rimini Street Support for its Oracle Applications and Database Software4.3.2021 15:05:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Kent County Council, the largest County Council in England, is switching support for its Oracle E-Business Suite 12.1 application and Oracle Database software to Rimini Street. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210304005642/en/ Kent County Council Switches to Rimini Street Support for its Oracle Applications and Database Software. (Photo: Business Wire) Digital Transformation Possible, Even with Constrained IT Budgets Like other public sector bodies in the UK, Kent County Council is under significant pressure to allocate its annual budget effectively to meet the challenges affecting the county. With 1,759 core users and 21,096 self-service users spread across the organization, as well as sch
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom